跳到正文
原文
NEJM· @NEJM · X·· 2 天前AI 评分43
AI 导读

在 IgA 肾病中,补体激活可导致血尿、蛋白尿和肾单位丢失。终末补体抑制剂 ravulizumab 能否降低蛋白尿?新一期 Quick Take 视频总结了 I CAN 试验的研究结果。https://nej.md/4sPRhTf

正文

In IgA nephropathy, complement activation leads to hematuria, proteinuria, and nephron loss. Does ravulizumab, a terminal complement inhibitor, reduce proteinuria? Research findings from the I CAN trial are summarized in a new Quick Take video. https://nej.md/4sPRhTf

来源:NEJM · x.com